Stay updated with breaking news from Subcutaneous Administration. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A recent study demonstrates that the monoclonal antibody-based vaccine L9LS is safe for children aged 6 to 10 and significantly reduces the risk of malaria infection and clinical symptoms by 70% and 77%, respectively.
One injected dose of an experimental malaria monoclonal antibody was 77% effective against malaria disease in children in Mali during the country’s six-month malaria season, according to the results of a mid-stage clinical trial. The trial assessed an investigational monoclonal antibody developed by scientists at the National Institutes of Health (NIH), and results appear in <em>The New England Journal of Medicine</em>.
The primary endpoint of the study was clinical remission at week 52 with vedolizumab
Experts discuss FDA-approved therapies for DLBCL (diffuse large B cell lymphoma) treatment, including formulations, efficacy profiles, administration impact, patient preferences, and institutional implications.
Press release – No. 18 / 2023 Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome Copenhagen, Denmark, December 22, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for glepaglutide, a long-acting GLP-2 analog, for th